Immunogenicity of a recombinant human immunodeficiency virus (HIV) - Canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV network for prevention trials 007 vaccine study

Journal of Infectious Diseases

Volumn 187, Issue 6, 2003, Pages 887-895

  Cao, Huyen ⁱ   Kaleebu, P ^e   Hom, D ^a   Flores, J ^b   Agrawal, D ^c   Jones, N ^j   Serwanga, J ^e   Okello, M ^f   Walker, C ^d   Sheppard, H ^j   El Habib, R ^h   Klein, M ^h   Mbidde, E ^g   Mugyenyi, P ^f   Walker, B ^c   Ellner, J ^a   Mugerwa, R ^g  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^f JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^g MAKERERE UNIVERSITY   (Uganda)

^h SANOFI PASTEUR   (France)

ⁱ VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; NEUTRALIZING ANTIBODY; PLACEBO; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ADULT; ANTIBODY RESPONSE; ARTICLE; CANARYPOX VIRUS; CLADISTICS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RABIES VIRUS; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; T LYMPHOCYTE; UGANDA; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; AIDS VACCINES; CANARYPOX VIRUS; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV SERONEGATIVITY; HIV-1; HUMANS; MALE; T-LYMPHOCYTES, CYTOTOXIC; UGANDA; VACCINATION; VACCINES, DNA;

EID: 0037444039     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368020     Document Type: Article

References (27)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO). AIDS epidemic update - December 2001. Geneva: UNAIDS/WHO, 2001.
2. Ezparza J. An HIV vaccine: how and when. Bull World Health Organ 2001; 79:1093.
3. Report W-U. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1. AIDS 2001; 15:W1-25.
4. Kaul R, Makadzange T, Rowland-Jones S. AIDS in Africa: a disaster no longer waiting to happen. Nat Immunol 2000; 1:267-70.
5. Yirrell DL, Kaleebu P, Morgan D, et al. Inter- and intra-genic inter-subtype HIV-1 recombination in rural and semi-urban Uganda. AIDS 2002; 16:279-86.
6. Kaleebu P, Whitworth J, Hamilton L, et al. Molecular epidemiology of HIV type 1 in a rural community in southwest Uganda. AIDS Res Hum Retroviruses 2000; 16:393-401.
7. Cao H, Mani I, Vincent R, et al. Cellular immunity to human immunodeficiency virus type 1(HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis 2000; 182:1350-6.
8. Yang OO, Kalams S, Rosenzwieg M, et al. Efficient lysis of HIV-1 infected cells by cytotoxic T lymphocytes. J Virol 1996; 70:5799-805.
9. Shiver J, Fu T, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-5.
10. Barouch D, Santra S, Schmitz J, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-92.
11. Rose MF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106:539-49.
12. Amara RR, Villenger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
13. Mugerwa R, Kaleebu P, Mugyenyi P, et al. First trial of the HIV-1 vaccine in Africa: Ugandan experience. HIV-1 Vaccine Trial Group. BMJ 2002; 324:226-9.
14. Belshe RB, Stevens C, Gorse JG, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. National Institute of Allergy, and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET). J Infect Dis 2001; 183:1343-52.
15. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with RGP120. The AIDS Vaccine Evaluation Group 022 Protocol Team. J Infect Dis 2001; 183:563-70.
16. Wong JT, Colvin RB. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987; 139:1369-74.
17. Wilson CC, Wong JT, Girard DD, et al. Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents. J Infect Dis 1995; 172:88-96.
18. Cao H, Agrawal D, Kushner N, Touzjian N, Essex M, Lu Y. Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol. J Infect Dis 2002; 185:244-51.
19. Cheingsong-Povov R, Callow D, Beddows S, et al. Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. J Infect Dis 1992; 165:256-61.
20. Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, Easterbrook P, Simmons P, Weber J. Neutralisation of primary and T-cell line adapted isolates of human immunodeficiency virus type: role of V3-specific antibodies. J Gen Virol 1998; 79:77-82.
21. Weber J, Fenyo E, Beddows S, Kaleebu P, Bjorndal A. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO network for HIV Isolation and Characterization. J Virol 1996; 70:7827-32.
22. Korber B, Brander C, Haynes B, et al. HIV Molecular Immunology 2000. Los Alamos; NM: Los Alamos National Laboratory, Theoretical Biology and Biophysics, 2000.
23. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:1230-46.
24. Corey L, McElrath MJ, Weinhold K, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine development. AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:301-9.
25. + cytotoxic T lymphocyte responses in seronegative volunteers. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1999; 180:290-8.
26. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192:63-75.
27. Kaslow R, Rivers C, Tang J, et al. Polymorphism in HLA class I genes associated with both favorable prognosis of human immnodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte response to ALVAC-HIV recombinant canarypox vaccine. NIAID AIDS Vaccine Evaluation Group. J Virol 2001; 75:8681-9.